BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9619916)

  • 1. Multidrug-resistant acute leukemia cells are responsive to prolonged exposure of daunorubicin: implications for liposome-encapsulated daunorubicin.
    Verdonck LF; Lokhorst HM; Roovers DJ; van Heugten HG
    Leuk Res; 1998 Mar; 22(3):249-56. PubMed ID: 9619916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD123/CD33 dual-antibody modified liposomes effectively target acute myeloid leukemia cells and reduce antigen-negative escape.
    Sun S; Zou H; Li L; Liu Q; Ding N; Zeng L; Li H; Mao S
    Int J Pharm; 2019 Sep; 568():118518. PubMed ID: 31319147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004.
    Creutzig U; Zimmermann M; Bourquin JP; Dworzak MN; Fleischhack G; Graf N; Klingebiel T; Kremens B; Lehrnbecher T; von Neuhoff C; Ritter J; Sander A; Schrauder A; von Stackelberg A; Starý J; Reinhardt D
    Blood; 2013 Jul; 122(1):37-43. PubMed ID: 23704089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposome-encapsulated daunorubicin for PGP-related multidrug resistance.
    Michieli M; Damiani D; Ermacora A; Masolini P; Michelutti A; Michelutti T; Russo D; Pea F; Baccarani M
    Br J Haematol; 1999 Jul; 106(1):92-9. PubMed ID: 10444168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia.
    Berman E; McBride M; Lin S; Menedez-Botet C; Tong W
    Leukemia; 1995 Oct; 9(10):1631-7. PubMed ID: 7564501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of multi-functional liposomes containing daunorubicin and emetine for treatment of acute myeloid leukaemia.
    Myhren L; Nilssen IM; Nicolas V; Døskeland SO; Barratt G; Herfindal L
    Eur J Pharm Biopharm; 2014 Sep; 88(1):186-93. PubMed ID: 24747809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia.
    Russo D; Piccaluga PP; Michieli M; Michelutti T; Visani G; Gugliotta L; Bonini A; Pierri I; Gobbi M; Tiribelli M; Fanin R; Piccolrovazzi S; Baccarani M
    Ann Hematol; 2002 Aug; 81(8):462-6. PubMed ID: 12224004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Doses of Daunorubicin during Induction Therapy of Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis of Prospective Clinical Trials.
    Gong Q; Zhou L; Xu S; Li X; Zou Y; Chen J
    PLoS One; 2015; 10(5):e0125612. PubMed ID: 25993000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia.
    Fassas A; Anagnostopoulos A
    Leuk Lymphoma; 2005 Jun; 46(6):795-802. PubMed ID: 16019523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of daunorubicin in the induction therapy for adult acute myeloid leukemia.
    Usui N; Dobashi N; Kobayashi T; Yano S; Maki N; Asai O; Saito T; Yamaguchi Y; Watanabe H; Kato A; Ogihara A; Katori M; Nagamine M; Takei Y; Yamazaki H; Funakoshi S; Tajima N; Ogawa M; Kuraishi Y
    J Clin Oncol; 1998 Jun; 16(6):2086-92. PubMed ID: 9626208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The role of daunorubicin in induction therapy for adult acute myeloid leukemia].
    Usui N; Dobashi N; Asai O; Yano S; Kato A; Osawa H; Uno S; Katori M; Nagamine M; Yahagi Y; Yamaguchi Y; Saito T; Kasama K; Takei Y; Ogihara A; Yamazaki H; Kobayashi T; Tajima N; Ogawa M; Kuraishi Y
    Gan To Kagaku Ryoho; 2000 Jul; 27(8):1152-9. PubMed ID: 10945010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia.
    Tidefelt U; Liliemark J; Gruber A; Liliemark E; Sundman-Engberg B; Juliusson G; Stenke L; Elmhorn-Rosenborg A; Möllgård L; Lehman S; Xu D; Covelli A; Gustavsson B; Paul C
    J Clin Oncol; 2000 May; 18(9):1837-44. PubMed ID: 10784624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomal daunorubicin plasmatic and renal disposition in patients with acute leukemia.
    Pea F; Russo D; Michieli M; Baraldo M; Ermacora A; Damiani D; Baccarani M; Furlanut M
    Cancer Chemother Pharmacol; 2000; 46(4):279-86. PubMed ID: 11052625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Palmar-plantar erythrodysesthesia syndrome associated with liposomal daunorubicin.
    Hui YF; Cortes JE
    Pharmacotherapy; 2000 Oct; 20(10):1221-3. PubMed ID: 11034047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daunorubicin-induced cell kill with 1-hour versus 24-hour infusions: a randomized comparison in children with newly diagnosed acute lymphoblastic leukemia.
    Escherich G; Göbel U; Jorch N; Spaar HJ; Janka-Schaub GE
    Klin Padiatr; 2007; 219(3):134-8. PubMed ID: 17525906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of the in vitro cytotoxicity of daunorubicin and liposomal daunorubicin in pediatric acute leukemia.
    Goemans BF; Zwaan CM; Reinhardt D; Gibson BE; Hählen K; Kaspers GJ
    Haematologica; 2006 Nov; 91(11):1573-4. PubMed ID: 17043024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation.
    Gordon MJ; Tardi P; Loriaux MM; Spurgeon SE; Traer E; Kovacsovics T; Mayer LD; Tyner JW
    Leuk Res; 2017 Feb; 53():39-49. PubMed ID: 28013106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcellular daunorubicin distribution and its relation to multidrug resistance phenotype in drug-resistant cell line SMMC-7721/R.
    Yang JY; Luo HY; Lin QY; Liu ZM; Yan LN; Lin P; Zhang J; Lei S
    World J Gastroenterol; 2002 Aug; 8(4):644-9. PubMed ID: 12174371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contrastive Studies of Cytarabine/Daunorubicin Dual-Loaded Liposomes Prepared by pH Gradient and Cu
    Zhang J; Zhou L; Zhang Y; He H; Yin T; Gou J; Wang Y; Tang X
    AAPS PharmSciTech; 2020 Nov; 21(8):325. PubMed ID: 33206247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted inhibition of ULK1 enhances daunorubicin sensitivity in acute myeloid leukemia.
    Qiu L; Zhou G; Cao S
    Life Sci; 2020 Feb; 243():117234. PubMed ID: 31887299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.